Blood Irradiator Market -
Regional Insights
On the basis of region, the
global Blood
Irradiator Market is segmented into North America, Latin America, Europe,
Asia Pacific, Middle East, and Africa. North America holds dominant position in
the global blood irradiators market, owing to the launch and adoption of novel
technologies. For instance, in September 2017, Typenex Medical, launched
Rad-Control, a new irradiation indicator tag technology in the blood banks and
blood centers in the U.S. and Canada. Rad-control ensures that blood component
has received irradiation, thereby preventing life threatening
transfusion-associated Graft-vs.-Host Disease (TA-GvHD).
Furthermore, increasing adoption
of X-ray irradiators is expected to fuel the blood irradiator market growth. In
2017, the U.S. Department of Energy’s National Nuclear Security Administration
(DOE/NNSA) partnered with the New York City Department of Health and Mental
Hygiene (DOHMH) and the Nuclear Threat Initiative (NTI) to replace the
radioactive irradiators with the safer X-ray alternatives.
Blood irradiators are used to
irradiate blood and blood components to prevent the proliferation of T
lymphocytes that can inhibit the immune response leading to graft-versus-host
disease (GVHD). The blood irradiators are widely used in various medical and
research applications such as preparing blood for transfusion and cancer
research. Irradiation procedure is necessary for transfusion recipients at risk
for GVHD, including fetuses receiving intrauterine transfusions, patients
undergoing hematopoietic transplantation, and individuals receiving platelets.
Blood irradiators has applications in irradiation of blood, which is essential
for surgeries, cancer treatment, chronic illnesses, and traumatic injuries.
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1972
Blood Irradiator Market Drivers
Irradiated blood is provided to
prevent rare complications of transfusion called transfusion- associated
graft-versus-host disease, a rare but serious complication of blood transfusion
caused by white blood cells in the blood transfused. According to the Royal
Children’s Hospital Melbourne, transfusion- associated graft-versus-host
disease (TA-GVHD) occurs when donor lymphocytes from transfused blood engraft
in the recipient, causing diseases such as hepatitis, diarrhea and pancytopenia
with clinical features of fever and skin rash and is fatal in more than 90% of
cases.
Moreover, support from government
organizations for development of novel irradiators to ensure safe blood
transfusions is driving market growth. For instance, in 2014, Stellarray, Inc.,
developer of novel x-ray sources, was awarded the US$ 1.1 Mn grant by the
Department of Energy to develop and commercialize new generation irradiators
for ensuring the safety of blood transfusions by replacing cesium, 137 which is
identified as a national security hazard.
Moreover, the Advancing
Transfusion Cellular Therapies Worldwide (AABB) works in collaboration with the
Food and Drug Administration (FDA) to ensure appropriate irradiation guidance
and regulations for blood products, thereby favoring the blood irradiators
market by maintaining security and compliance to limit the use of radioactive
irradiators.
However, the lack of awareness
among population regarding uses and benefits of irradiators in the healthcare
facilities and high cost of the irradiators are the factors hindering the
market growth. For instance, according to the survey by College of American
Pathologists, 2017, the cost of X-ray irradiators is around US$ 250,000 to US$
300,000, with annual service contract accounting for US$ 15,000 to US$ 20,000.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/blood-irradiator-market-1972
Moreover, increasing number of
cases requiring blood transfusions related to various diseases in the region is
a major factor favoring the market growth. According to the American National
Red Cross, sickle cell disease affects 90,000 to 100,000 people in the U.S.,
and about 1,000 babies are born with the disease annually. The sickle cell
patients mostly require blood transfusions throughout their lives. Also,
according to the American Cancer Society, about 1.7 million people are expected
to be diagnosed with cancer in 2017, where the patients require blood during
the chemotherapy treatment.
Moreover, high adoption of blood
irradiators in the medical settings to prevent and control the transmission of
transfusion associated graft-versus-host disease (TA-GVHD) is expected to
propel market growth in the North America. According to the Department of
Health and Human Services, 2013, around 500 blood irradiators irradiated around
2 million blood units in 2013.
Blood Irradiator Market -
Competitive Landscape
Key players in the global blood
irradiator market are focused on strategic mergers and acquisitions to promote
the blood irradiators in the global market. For instance, Charter Medical
collaborated with RadTag Technologies to distribute the RadTag blood irradiator
indicators in the U.S.
Some of the key players operating
in the global blood irradiator market include Rad Source Technologies, Sukosol
Group, Typenex Medical, Gamma-Service Medical GmbH, Cegelec NDT-PES, and Best
Theratronics, Ltd.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1972
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment